[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 827,562
  • Shares Outstanding, K 641,521
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -83,500 K
  • EBIT $ -35 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.68
  • Price/Sales 4.88
  • Price/Cash Flow N/A
  • Price/Book 3.94

Options Overview Details

View History
  • Implied Volatility 123.53% (+13.96%)
  • Historical Volatility 57.28%
  • IV Percentile 53%
  • IV Rank 15.98%
  • IV High 429.98% on 10/10/25
  • IV Low 65.22% on 06/04/25
  • Expected Move (DTE 33) 0.2720 (21.09%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 1,630
  • Volume Avg (30-Day) 749
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 53,549
  • Open Int (30-Day) 51,327
  • Expected Range 1.0180 to 1.5620

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 4
  • High Estimate $0.00
  • Low Estimate $-0.01
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2850 +0.39%
on 05/15/26
1.7400 -25.86%
on 04/17/26
-0.4000 (-23.67%)
since 04/15/26
3-Month
1.2850 +0.39%
on 05/15/26
2.0100 -35.82%
on 02/19/26
-0.3600 (-21.82%)
since 02/13/26
52-Week
1.0400 +24.04%
on 11/07/25
2.0100 -35.82%
on 02/19/26
+0.0800 (+6.61%)
since 05/15/25

Most Recent Stories

More News
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population  Additional presentations...

GERN : 1.2900 (-7.86%)
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating...

GERN : 1.2900 (-7.86%)
Geron's First Commercial Quarter Tests Whether Rytelo Launch Momentum Holds

Barchart Research What to Expect from GERN Earnings GERN Generated May 5, 2026 Current Price $1.6500 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 8.78% Geron's First Commercial Quarter...

GERN : 1.2900 (-7.86%)
Geron Plans to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.2900 (-7.86%)
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.2900 (-7.86%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock...

GERN : 1.2900 (-7.86%)
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a...

GERN : 1.2900 (-7.86%)
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

FOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.2900 (-7.86%)
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.2900 (-7.86%)

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.4800
2nd Resistance Point 1.4400
1st Resistance Point 1.3650
Last Price 1.2900
1st Support Level 1.2500
2nd Support Level 1.2100
3rd Support Level 1.1350

See More

52-Week High 2.0100
Fibonacci 61.8% 1.6395
Fibonacci 50% 1.5250
Fibonacci 38.2% 1.4105
Last Price 1.2900
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.